Search | Clinical Trials Finder

Conditions: Seasonal Allergic Rhinitis
Interventions: Fluticasone propionate, Flonase®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years and older
Enrollment: 1,474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Perennial Allergic Rhinitis
Interventions: Olopatadine hydrochloride 0.6% nasal spray (PATANASE), Olopatadine nasal spray vehicle, pH 3.7, Olopatadine nasal spray vehicle, pH 7.0; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 12 Years and older
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions: Intra-lymphatic allergenic extract, Intra-lymphatic placebo; Biological
Lead sponsor: Christopher Thompson, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Austin, Texas • Grapevine, Texas • San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis, Hay Fever
Interventions: Beclomethasone dipropionate, Placebo Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Depression
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo comparator, Grass MATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 4
States / cities: Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more

Conditions: Asthma, Seasonal Allergic Rhinitis
Interventions: Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID; Drug
Lead sponsor: Creighton University; Other
Eligibility: 15 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Allergic Rhinitis, Chronic Urticaria
Interventions: Levocetirizine, Placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more

Conditions: Seasonal Allergic Rhinitis
Interventions: MP29-02, azelastine Hcl, fluticasone propionate, placebo; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Allergic Rhinitis, Conjunctivitis
Interventions: REGN5713, REGN5714, REGN5715, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 14
States / cities: Bangor, Maine • Baltimore, Maryland • Plymouth, Minnesota + 11 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas

Conditions: Hay Fever, Perennial Allergic Rhinitis
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Long Beach, California • Normal, Illinois • San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: STAHIST, Placebo; Drug
Lead sponsor: Magna Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Stockbridge, Georgia • South Bend, Indiana • Louisville, Kentucky + 5 more

Conditions: Seasonal Allergic Rhinitis
Interventions: triamcinolone acetonide aqueous nasal spray (Apotex Inc.), triamcinolone acetonide aqueous nasal spray (Nasacort® AQ), Placebo; Drug
Lead sponsor: Apotex Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Seasonal Allergic Rhinitis
Interventions: PL nasal spray, fluticasone furoate (FF), PL eye drops, olopatadine (OLO); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions: PQ Grass, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 33
States / cities: Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more

Conditions: Rhinitis, Allergic, Perennial and Seasonal
Interventions: FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 31
States / cities: Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Fexofenadine HCl; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 15 Years and older
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Seasonal Allergic Rhinitis
Interventions: Olopatadine HCL Nasal Spray, 0.6%, Fluticasone Propionate Nasal Spray, 50 mcg; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 12 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Rhinitis, Allergic, Seasonal
Interventions: fluticasone furoate, fexofenadine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 42
States / cities: Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray, Placebo nasal spray; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 30
States / cities: Stockbridge, Georgia • Louisville, Kentucky • Baltimore, Maryland + 21 more

Conditions: Hay Fever
Interventions: topical nasal rEV131; Drug
Lead sponsor: Evolutec Group; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 2
States / cities: San Antonio, Texas

Search by objective public record fields.

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

Examining the Link Between Depression and Seasonal Allergies

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Trial of STAHIST in Seasonal Allergic Rhinitis

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit

Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis

Safety and Efficacy Study of rEV131 in Allergic Rhinitis